Completed NA INTERVENTIONAL 2-arm NCT00943267

Effect of Intrapulmonary Recombinant Human Activated Protein C (APC) on Coagulation and Inflammation After Lipopolysaccharide (LPS)

Effect of Intrapulmonary Administration of Recombinant Human Activated Protein C on Local Coagulation and Inflammation After Bronchial Instillation of Lipopolysaccharide in Humans

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Conditions Lipopolysaccharides Pneumonia

Interventions Blood sampling Bronchoscopy Drotrecogin alpha Endotoxin Saline (NaCl 0.9%)

Updated 5 times since 2017 Last updated: Mar 15, 2011 Started: Oct 31, 2008 Primary completion: Aug 31, 2010 Completion: Mar 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Lipopolysaccharides and Pneumonia, this trial is completed. The trial is conducted by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) and has accumulated 5 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Data source: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Amsterdam, Netherlands